Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ5O3K)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutaminase (GLS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CB-839	DM094UH	Breast cancer	2C60-2C65	Phase 2	[2]
PMID30273516-Compound-39	DMBF3ZE	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-13	DMK9TJP	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-22a	DMVZA0U	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-37	DM8NBJV	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-12	DMIWEZH	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-38	DMRPJBF	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-1	DM52MKV	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-15	DMSD647	N. A.	N. A.	Patented	[1]
PMID30273516-Compound-41	DM5UBMJ	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835.
2	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.